Category: Press Releases

Posted on

Africa’s top 20 Best Places to Work revealed

LONDON, Jan. 10, 2022 /PRNewswire/ — The Best Places to Work organization announced today the top 20 Best Places to Work in Africa for 2022. The program recently compiled its annual list based on the assessment of over 500 organizations operating across the continent. Findings from this year indicated that the top performing organizations in Africa continued to invest in creating a highly-engaged workforce, with an average engagement score of 81%, compared with a market average of 69%. Additionally, 92% of top ranked organizations invested in having the right HR technology to improve productivity that could drive future success.

Topping this year’s ranking was Lundbeck, a global pharmaceutical company engaged in the research, development, manufacturing, marketing and sale of pharmaceuticals followed by Teleperformance, a leading global service provider in Customer Interaction and Process Management. Zoetis, a global animal health company secured the third position. To be considered, companies must be identified as outstanding employers at least in one of the countries across the continent.

The ranking was determined based on feedback from employees gathered through anonymous surveys and an HR assessment evaluating the people management practices against the best workplace standards.

The top 20 list includes:

  1. Lundbeck
  2. Teleperformance
  3. Zoetis
  4. Groupe Vipp
  5. Comdata Group
  6. Novo Nordisk
  7. BSH
  8. Chaabi LLD
  9. Ekuity Capital
  10. STKE
  11. SG ATS
  12. iNova Pharmaceuticals
  13. Somezzo
  14. Schindler
  15. Coface
  16. Meridiam
  17. Roche
  18. Paps
  19. Ipsen Pharma
  20. IHS Towers

“This year’s Best employers in Africa demonstrated open communication and top team alignment, with clear differentiators of having a continuous approach across employee experience initiatives,” commented Hamza Idrissi, Program Manager for the Best Places to Work in Africa.

ABOUT BEST PLACES TO WORK PROGRAM

Best Places to Work is the most definitive ‘Employer of Choice’ certification that organizations aspire to achieve. Every year, the program certifies and recognizes leading workplaces in many countries around the world with a rigorous assessment methodology and a framework which reflects the very latest in workplace trends focusing on 8 Workplace factors including leadership, HR & people policies, compensation, benefits, teamwork & relationships, employee engagement, workplace & procedures and corporate social responsibility. 

For more information, please visit www.bestplacestoworkfor.org

Posted on

Cuentas Signs Binding Letter of Intent to Purchase SDI Black 011 LLC and Mango Tel LLC for $3.2M

Acquisition Will Expand Cuentas’ Retail and Mobile Reach and Drive Growth in Key Target Markets

MIAMI, FL / ACCESSWIRE / January 10, 2022 / Cuentas, Inc. (NASDAQ:CUEN)(NASDAQ:CUENW) (“Cuentas”), a leading fintech provider of mobile banking and payment solutions, has signed a binding letter of intent to acquire the operations and distribution network of prepaid wireless and digital provider SDI Black 011 (SDI), as well as Mango Mobile and Black Wireless. The deal is expected to close by or before May of this year.pic2152

Cuentas previously invested in the expansion of the SDI network, and will leverage these assets to accelerate reach of the Cuentas prepaid debit card and digital wallet via retail, mobile and other channels. SDI generated more than $9 million in retail revenue in 2021.

“This acquisition will drive more recurring revenue and create new operational efficiencies for Cuentas.” said Jeff Johnson, CEO of Cuentas. “We expect SDI’s profitable assets to contribute to economies of scale across our business, and enable more solutions within the Cuentas mobile app, driving higher profits and accelerating market growth in our core fintech business.”

The SDI B2B portal serves over 30,000 US bodegas, wireless retailers and convenience stores, and will enable retailers to sell from a portfolio of hundreds of virtual products without carrying inventory, generating incremental profits in real-time.

Black011 and its brands already have hundreds of thousands of subscribers who purchase services via the SDI website and digital portal, both of which connect via API to the largest wireless companies in the world. This technology allows SDI to be one of the largest distribution channels for wireless services in the New York City metro tri-state area and nationwide.

Through this acquisition, both retailers and Black011 subscribers will benefit from access to Cuentas solutions including the Cuentas Prepaid Debit card, OMNY Transit, Amazon cash, prepaid gift cards, rebates, new offers and more.

About Cuentas

Cuentas, Inc. (Nasdaq: CUEN & CUENW) is a fintech e-banking and e-commerce service provider with proprietary technology that delivers digital financial services to the underbanked and un-banked Hispanic, Latino and immigrant population including mobile and online banking, prepaid debit, ACH and mobile deposits, cash remittance, peer to peer money transferring, and other services. The Cuentas General Purpose Reloadable (GPR) Card includes a digital wallet, discounts for purchases at major

physical and online retailers, rewards, and the ability to purchase digital content. For more information, visit https://cuentas.com

Forward-Looking Statements

This news release contains “forward-looking statements,” as that term is defined in section 27a of the United States Securities Act of 1933, as amended, and section 21e of the United States Securities Exchange Act of 1934, as amended. Statements in this press release, which are not purely historical, are forward-looking statements and include any statements regarding beliefs, plans, expectations, or intentions regarding the future. Except for the historical information presented herein, matters discussed in this news release contain forward-looking statements that are subject to certain risks and uncertainties that could cause actual results to differ materially from any future results, performance or achievements expressed or implied by such statements. Statements that are not historical facts, including statements that are preceded by, followed by, or that include such words as “believe,” “plan,” or “expect” or similar statements are forward-looking statements.

Investor Relations

Cuentas, Inc.
800-611-3622
info@cuentas.com

SOURCE: Cuentas, Inc.

 

Posted on

En 2022, Hisense prévoit de commercialiser davantage de produits d’affichage performants et de haute qualité sur le marché africain

JOHANNESBURG, Afrique du Sud, 7 janvier 2022 /PRNewswire/ — Hisense, fournisseur de téléviseurs et d’appareils électroménagers haute performance, a présenté sa solution de technologie d’affichage laser à résolution 8K et la série ULED 8K Mini-LED lors du récent Consumer Electronics Show 2022 (« CES 2022 »), qui s’est tenue à Las Vegas. Suite à la présentation du premier écran laser 8K domestique au monde lors de l’événement technologique le plus influent sur la planète, Hisense présentera en janvier deux autres produits haut de gamme sur le marché africain, ainsi que d’autres produits plus performants plus tard en 2022.

Hisense Plans to Bring More High Performing and High-quality Display Products to African Market in 2022

« Grâce à l’innovation technologique continue, Hisense surmonte les obstacles techniques, faisant passer les téléviseurs laser de 1080P à 2K, puis à 4K et désormais à 8K et propulsant l’industrie mondiale de la télévision laser dans l’ère du TriChroma. Nous nous engageons à apporter des produits dignes de confiance à des millions de nos utilisateurs en Afrique grâce à un design exceptionnel, une technologie de pointe et un excellent service », a déclaré Patrick Hu, directeur marketing d’Hisense South Africa.

Doté du moteur laser TriChroma de Hisense, qui atteint une luminosité maximale de 3 000 lumens, le téléviseur TriChroma L9G sera disponible en Afrique en janvier. Il s’agit d’un téléviseur de projection 4K ultra court avec un triple laser, utilisant des lasers rouges, verts et bleus purs pour atteindre de nouveaux niveaux de performance de couleur. Il a remporté le « King of Ultra Short Throw Projectors », a été nommé « Best in Class » par Projector Reviews et a été désigné comme étant le choix de la rédaction par Projector Central en 2021.

En plus du L9G, Hisense lancera également le téléviseur 4K Mini LED U9G sur le marché africain ce mois-ci. En juin 2022, le nouveau téléviseur 4K Mini LED U8H fera bénéficier les consommateurs de la région d’un plus grand nombre de mises à niveau haut de gamme et de performances de qualité. Avec des tailles d’écran allant de 55 à 75 pouces, le taux de rafraîchissement natif de 120 Hz de l’U8H permet de traiter en douceur mouvements et luminosité, magnifiant à l’écran les films d’action et les sports.

En 2022, Hisense implémente pour la première fois sa technologie Mini LED dans son nouveau téléviseur premium 8K Mini LED, offrant une performance HDR époustouflante avec un meilleur contraste, des images plus lumineuses et des couleurs plus impressionnantes que jamais. Le téléviseur Hisense 8K Mini LED a remporté le prix de l’innovation CES® 2022. Cette technologie de pointe sera également commercialisée sur le marché africain. Le téléviseur phare U80H 8K Mini LED devrait être lancé sur le marché africain en juillet 2022.

Photo – https://mma.prnewswire.com/media/1721327/Hisense.jpg

Posted on

Zenas BioPharma nomme le Dr John Orloff au Conseil d’administration

BOSTON et SHANGHAI, Chine, 06 janv. 2022 (GLOBE NEWSWIRE) — Zenas BioPharma, une société biopharmaceutique mondiale déterminée à devenir un leader dans le développement et la fourniture de traitements immunitaires, a annoncé aujourd’hui la nomination de John Orloff, MD, à son Conseil d’administration. Le Dr Orloff rejoint le Conseil d’administration de Zenas avec plus de 25 ans d’expérience à la tête d’organisations mondiales de recherche et de développement dans plusieurs domaines thérapeutiques, y compris les maladies auto-immunes.

« Nous sommes extrêmement heureux d’accueillir le Dr Orloff au sein du Conseil d’administration de Zenas », a déclaré Lonnie Moulder, fondateur et président exécutif de Zenas. « Le leadership de John et sa vaste expertise dans la recherche, le développement et les affaires médicales et réglementaires seront inestimables alors que nous faisons progresser notre portefeuille de traitements immunitaires innovants et continuons d’étendre notre pipeline via le développement commercial. »

« Je suis ravi de travailler avec l’équipe de direction de Zenas et ses autres directeurs alors que la société progresse rapidement dans un pipeline passionnant de traitements immunitaires », a commenté le Dr Orloff. « Je suis impatient de contribuer au développement continu de la société alors qu’elle s’efforce de remplir sa mission visant à apporter des médicaments innovants aux patients dans le besoin. »

Le Dr Orloff est actuellement partenaire d’investissement chez Agent Capital. À son poste de direction le plus récent, il était vice-président exécutif et responsable de la recherche et du développement chez Alexion où son leadership dans l’expansion du pipeline de développement à 30 programmes a soutenu la récente acquisition d’Alexion par AstraZeneca pour un montant de 39 milliards de dollars.

Avant Alexion, le Dr Orloff a occupé les postes de directeur mondial de la R&D et de directeur scientifique chez Baxalta, ainsi que des postes de direction chez Novelion, Baxter International, Merck Serono, Novartis et Merck Research Laboratories. Avant d’entrer dans l’industrie biopharmaceutique, il était membre du corps professoral de la Yale University School of Medicine. Le Dr Orloff est titulaire d’un diplôme de premier cycle en chimie du Dartmouth College, d’un diplôme de médecine de l’université de Vermont, College of Medicine, et d’une bourse d’études en endocrinologie et métabolisme à la Yale University School of Medicine.

À propos de Zenas BioPharma

Zenas BioPharma est une société biopharmaceutique mondiale basée en Chine et aux États-Unis déterminée à devenir un leader dans le développement et la fourniture de traitements immunitaires pour les patients aux États-Unis, en Chine et dans le monde entier. Zenas fait rapidement progresser un vaste pipeline de traitements innovants qui continue de s’accroître grâce à notre stratégie de développement commercial fructueuse. Notre équipe de direction expérimentée et notre réseau de partenaires commerciaux stimulent l’excellence opérationnelle pour apporter des thérapies potentiellement transformatrices afin d’améliorer la vie des personnes confrontées à des maladies rares et auto-immunes. Pour tout complément d’information sur Zenas BioPharma, veuillez consulter le site www.zenasbio.com et nous suivre sur Twitter à l’adresse @ZenasBioPharma et LinkedIn.

Contact auprès des investisseurs et des médias :
Joe Farmer
Zenas BioPharma
IR@zenasbio.com

Posted on

Zenas BioPharma Nomeia Dr. John Orloff para o Conselho Diretor

BOSTON e XANGAI, China, Jan. 06, 2022 (GLOBE NEWSWIRE) — A Zenas BioPharma, uma empresa biofarmacêutica global comprometida em se tornar líder no desenvolvimento e entrega de terapias imunológicas, anunciou hoje a nomeação de John Orloff, MD para seu Conselho Diretor. O Dr. Orloff traz para o Conselho da Zenas seus mais de 25 anos de experiência liderando com sucesso organizações globais de pesquisa e desenvolvimento em várias áreas terapêuticas, incluindo doenças autoimunes.

“É com muito prazer que damos as boas-vindas ao Dr. Orloff ao Conselho Diretor da Zenas”, disse Lonnie Moulder, Fundador e Presidente Executivo da Zenas. “A liderança e a ampla experiência em pesquisa, desenvolvimento e assuntos médicos e regulatórios de John serão inestimáveis para o avanço do nosso portfólio de terapêuticas inovadoras com base em imunologia e para a contínua expansão do nosso pipeline por meio do desenvolvimento de negócios.”

“Será um grande prazer trabalhar com a equipe de liderança da Zenas e meus colegas diretores para o avanço rápido da empresa com um emocionante pipeline imunológico”, disse o Dr. Orloff. “Estou pronto para contribuir para o desenvolvimento contínuo da Empresa, no seu esforço em cumprir sua missão de levar medicamentos inovadores para os pacientes que precisam.”

O Dr. Orloff atualmente é sócio de empreendimento da Agent Capital. Na sua função executiva mais recente, ele foi Vice-Presidente Executivo e Chefe de Pesquisa e Desenvolvimento da Alexion, onde sua liderança na expansão do pipeline de desenvolvimento de 30 programas deu suporte à recente aquisição da Alexion pela AstraZeneca, no valor de US$ 39 bilhões.

Antes da Alexion, o Dr. Orloff foi Dirigente Global de P&D e Diretor Científico da Baxalta, e também ocupou cargos de liderança executiva na Novelion, Baxter International, Merck Serono, Novartis e Merck Research Laboratories. Antes de ingressar na indústria biofarmacêutica, ele foi membro do corpo docente da Yale University School of Medicine. O Dr. Orloff é formado em química pelo Dartmouth College, em medicina pelo College of Medicine da University of Vermont, e completou um fellowship em endocrinologia e metabolismo na Yale University School of Medicine.

Sobre a Zenas BioPharma

A Zenas BioPharma é uma empresa biofarmacêutica mundial com sedes nos EUA e na China, comprometida em se tornar líder global no desenvolvimento e oferta de terapias imunológicas para pacientes nos EUA, China e em todo o mundo. A Zenas está avançando rapidamente um vasto pipeline de terapêuticas inovadoras que continua a crescer por meio da nossa estratégia de desenvolvimento de negócios de sucesso. Nossa experiente equipe de liderança e rede de parceiros de negócios impulsionam a excelência operacional para oferecer terapias potencialmente transformadoras para melhorar a vida das pessoas que enfrentam doenças autoimunes e raras. Para mais informação sobre a Zenas BioPharma, visite www.zenasbio.com e siga-nos no Twitter em @ZenasBioPharma e LinkedIn.

Contato com Investidores e com a Mídia:
Joe Farmer
Zenas BioPharma
IR@zenasbio.com

Posted on

Hisense Plans to Bring More High Performing and High-quality Display Products to African Market in 2022

JOHANNESBURG, South Africa, Jan. 6, 2022 /PRNewswire/ — Hisense, provider of high-performance televisions and appliances, showcased its 8K resolution laser display technology solution and ULED 8K Mini-LED series at the recent Consumer Electronics Show 2022 (“CES 2022”) held in Las Vegas. Following the introduction of the world’s first 8K laser display for homes at the most influential tech event in the world, Hisense will introduce two more high-end products to the African market this January, with more high performing products coming later in 2022.

Hisense Plans to Bring More High Performing and High-quality Display Products to African Market in 2022

“Through continuous technological innovation, Hisense is breaking through technical barriers bringing laser TVs from 1080P to 2K to 4K and now on to 8K, driving the global laser TV industry into the TriChroma era. We are committed to bringing trustworthy products to millions of our users in Africa through outstanding design, leading technology and excellent service,” said Patrick Hu, marketing director of Hisense South Africa.

Featuring Hisense’s TriChroma laser engine that reaches up to 3000 lumens peak brightness, the L9G TriChroma Laser TV will be available in the region of Africa this January. It is a 4K ultra short throw projection TV with a triple-laser, using pure red, green, and blue lasers to achieve new levels of color performance. It has won the “King of Ultra Short Throw Projectors” and named Best in Class by Projector Reviews and awarded Editor’s Choice by Projector Central in 2021.

In addition to the L9G, Hisense will also launch the 4K Mini-LED U9G TV in the African market this month. In June 2022, the new 4K Mini-LED U8H TV will bring even more premium upgrades and quality performance to consumers in the region. With screen sizes ranging from 55 to 75-inches, the 120Hz native refresh rate of the U8H provides a foundation for smooth clarity and motion handling, making action movies and sports look great on the screen.

In 2022, Hisense is implementing its Mini LED technology into its new premium 8K Mini-LED TV product for the first time, delivering stunning HDR performance with better contrast, brighter images, and more impressive colors than ever before. Hisense 8K Mini LED TV won CES® 2022 Innovation Award, and this advanced technology will also be brought to the African market. The flagship U80H 8K Mini LED TV is set to be launched in the African market in July 2022.

Photo – https://mma.prnewswire.com/media/1721327/Hisense.jpg

 

Posted on

Zenas BioPharma Appoints Dr. John Orloff to Board of Directors

BOSTON and SHANGHAI, China, Jan. 06, 2022 (GLOBE NEWSWIRE) — Zenas BioPharma, a global biopharmaceutical company committed to becoming a leader in the development and delivery of immune-based therapies, today announced the appointment of John Orloff, MD to its Board of Directors. Dr. Orloff joins the Zenas Board with over 25 years of experience successfully leading global research and development organizations across multiple therapeutic areas including autoimmune diseases.

“We are extremely pleased to welcome Dr. Orloff to the Zenas Board of Directors,” said Lonnie Moulder, Founder and Executive Chairman of Zenas. “John’s leadership and extensive expertise in research, development, and medical and regulatory affairs will be invaluable as we advance our portfolio of innovative immune-based therapeutics and continue to expand our pipeline via business development.”

“I am delighted to work with the Zenas leadership team and fellow directors as the Company rapidly progresses an exciting immune-based pipeline,” said Dr. Orloff. “I look forward to contributing to the Company’s continued development as it strives to deliver on its mission to bring innovative medicines to patients in need.”

Dr. Orloff currently serves as a venture partner with Agent Capital. In his most recent executive role, he served as Executive Vice President and Head of Research and Development at Alexion where his leadership in expanding the development pipeline to 30 programs supported the recent $39 billion acquisition of Alexion by AstraZeneca.

Prior to Alexion, Dr. Orloff served as Global Head of R&D and Chief Scientific Officer at Baxalta, and has also held executive leadership roles with Novelion, Baxter International, Merck Serono, Novartis and Merck Research Laboratories. Before entering the biopharmaceutical industry, he was a faculty member of the Yale University School of Medicine. Dr. Orloff received an undergraduate degree in chemistry from Dartmouth College, earned his medical degree from the University of Vermont, College of Medicine and completed a fellowship in endocrinology and metabolism at Yale University School of Medicine.

About Zenas BioPharma

Zenas BioPharma is a global biopharmaceutical company based in the USA and China committed to becoming a leader in the development and delivery of immune-based therapies for patients in the US, China and around the world. Zenas is rapidly advancing a deep pipeline of innovative therapeutics that continues to grow through our successful business development strategy. Our experienced leadership team and network of business partners drive operational excellence to deliver potentially transformative therapies to improve the lives of those facing autoimmune and rare diseases. For more information about Zenas BioPharma, please visit www.zenasbio.com and follow us on Twitter at @ZenasBioPharma and LinkedIn.

Investor and Media Contact:
Joe Farmer
Zenas BioPharma
IR@zenasbio.com